Share Price and Basic Stock Data
Last Updated: November 22, 2025, 8:57 am
| PEG Ratio | 0.92 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Kingfa Science & Technology (India) Ltd operates in the plastics sector, particularly focusing on plastic and plastic products. The company reported a significant increase in sales, rising from ₹1,048 Cr in FY 2022 to ₹1,404 Cr in FY 2023, marking a growth of approximately 34%. For FY 2025, sales are projected to rise further to ₹1,745 Cr, indicating a robust growth trajectory. Quarterly sales data reveals fluctuations, with the highest quarterly sales of ₹404 Cr recorded in Mar 2024. This trend underscores the company’s ability to navigate market challenges effectively. The operating profit margin (OPM) for FY 2025 stood at 13%, reflecting a steady operational performance compared to previous years. Overall, Kingfa Science & Technology has demonstrated resilience, maintaining a positive revenue trend despite market volatility, which positions it favorably within the competitive landscape of the plastics industry.
Profitability and Efficiency Metrics
In terms of profitability, Kingfa Science & Technology has shown commendable performance with a net profit of ₹157 Cr for FY 2025, up from ₹81 Cr in FY 2023. The net profit margin for FY 2025 stood at 8.76%, indicating improved profitability compared to previous years. The company has also maintained a high return on equity (ROE) of 23.2%, which is above industry averages, signifying efficient use of shareholder funds. The return on capital employed (ROCE) also reflects strong operational efficiency at 30.6%. The interest coverage ratio (ICR) is notably high at 35.23x, suggesting that the company comfortably meets its interest obligations. However, the operating profit margin has shown slight fluctuations, with a recorded high of 15% in Mar 2023, indicating potential areas for operational improvement. Overall, the metrics reflect a solid profitability framework, although consistent OPM improvement will be essential for sustained growth.
Balance Sheet Strength and Financial Ratios
Kingfa Science & Technology’s balance sheet exhibits strength, with total assets reported at ₹1,156 Cr as of Mar 2025. The company has maintained a low level of borrowings, which stood at ₹43 Cr, reflecting a conservative financial strategy that minimizes risk. Reserves increased significantly from ₹372 Cr in FY 2022 to ₹716 Cr in FY 2025, demonstrating the company’s capacity to reinvest in growth. The current ratio of 2.02x indicates strong liquidity, allowing the company to cover short-term liabilities comfortably. Moreover, the debt-to-equity ratio remains low at 0.05, highlighting minimal reliance on debt financing. The price-to-book value (P/BV) ratio is recorded at 4.92x, which suggests that the market values the company at a premium compared to its book value, reflecting investor confidence. These factors collectively underscore a robust financial position, providing a solid foundation for future expansion initiatives.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Kingfa Science & Technology indicates a strong promoter holding of 67.02% as of Mar 2025, which reflects significant insider confidence in the company’s future. Foreign institutional investors (FIIs) have a stake of 7.78%, while domestic institutional investors (DIIs) hold 8.75%, suggesting a balanced institutional interest. The total number of shareholders stands at 12,610, indicating a growing investor base. However, the decline in promoter holding from 74.99% to 67.02% over the reporting periods may raise concerns among some investors regarding insider commitment. Public shareholding has also decreased to 16.45%, which could imply that retail investors are becoming more cautious amidst market fluctuations. Overall, while there is strong institutional support, the changes in promoter and public holdings warrant close monitoring as they may influence market perceptions and investor confidence.
Outlook, Risks, and Final Insight
Looking ahead, Kingfa Science & Technology is well-positioned to capitalize on the growing demand for sustainable plastic solutions, particularly as industries shift towards eco-friendly materials. The company’s strong financial metrics and operational efficiency provide a solid platform for continued growth. However, risks such as fluctuating raw material prices and potential regulatory changes in the plastics industry could pose challenges. Additionally, competition within the sector remains intense, which could pressure margins. If Kingfa maintains its operational efficiency and continues to innovate, it can potentially enhance its market position. Conversely, if external factors such as economic downturns or supply chain disruptions occur, they could adversely impact performance. Addressing these risks while leveraging strengths will be crucial for sustaining growth in the dynamic plastics market.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Kingfa Science & Technology (India) Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| IIRM Holdings India Ltd | 511 Cr. | 75.0 | 135/69.7 | 27.8 | 21.3 | 0.00 % | 23.5 % | 18.6 % | 5.00 |
| Fiberweb (India) Ltd | 112 Cr. | 38.8 | 66.0/34.0 | 6.94 | 63.9 | 0.00 % | 10.0 % | 8.88 % | 10.0 |
| Deep Polymers Ltd | 110 Cr. | 45.7 | 74.2/35.7 | 22.3 | 37.5 | 0.00 % | 8.22 % | 6.10 % | 10.0 |
| DDev Plastiks Industries Ltd | 3,071 Cr. | 296 | 360/213 | 15.5 | 88.5 | 0.59 % | 33.9 % | 24.9 % | 1.00 |
| Bright Brothers Ltd | 168 Cr. | 295 | 495/264 | 21.0 | 141 | 0.85 % | 16.2 % | 11.5 % | 10.0 |
| Industry Average | 1,592.42 Cr | 472.03 | 36.45 | 190.74 | 0.30% | 16.69% | 12.44% | 8.13 |
All Competitor Stocks of Kingfa Science & Technology (India) Ltd
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 346 | 351 | 340 | 366 | 339 | 351 | 394 | 404 | 416 | 418 | 440 | 470 | 462 |
| Expenses | 338 | 317 | 310 | 311 | 289 | 306 | 356 | 354 | 359 | 362 | 389 | 409 | 404 |
| Operating Profit | 8 | 34 | 31 | 55 | 50 | 45 | 38 | 51 | 57 | 56 | 51 | 60 | 58 |
| OPM % | 2% | 10% | 9% | 15% | 15% | 13% | 10% | 13% | 14% | 13% | 12% | 13% | 13% |
| Other Income | 0 | 1 | 1 | 1 | 2 | 0 | 1 | 2 | 2 | 1 | 5 | 2 | 4 |
| Interest | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 |
| Depreciation | 3 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 6 | 6 |
| Profit before tax | 3 | 30 | 27 | 49 | 47 | 40 | 32 | 45 | 52 | 50 | 49 | 54 | 54 |
| Tax % | 27% | 26% | 25% | 26% | 25% | 25% | 25% | 26% | 25% | 26% | 30% | 23% | 26% |
| Net Profit | 2 | 22 | 20 | 37 | 35 | 30 | 24 | 34 | 39 | 37 | 35 | 42 | 40 |
| EPS in Rs | 2.04 | 18.24 | 16.70 | 30.24 | 28.93 | 24.44 | 20.09 | 27.70 | 32.26 | 30.77 | 28.60 | 34.60 | 32.86 |
Last Updated: August 1, 2025, 6:20 pm
Below is a detailed analysis of the quarterly data for Kingfa Science & Technology (India) Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 462.00 Cr.. The value appears to be declining and may need further review. It has decreased from 470.00 Cr. (Mar 2025) to 462.00 Cr., marking a decrease of 8.00 Cr..
- For Expenses, as of Jun 2025, the value is 404.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 409.00 Cr. (Mar 2025) to 404.00 Cr., marking a decrease of 5.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 58.00 Cr.. The value appears to be declining and may need further review. It has decreased from 60.00 Cr. (Mar 2025) to 58.00 Cr., marking a decrease of 2.00 Cr..
- For OPM %, as of Jun 2025, the value is 13.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 13.00%.
- For Other Income, as of Jun 2025, the value is 4.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Mar 2025) to 4.00 Cr., marking an increase of 2.00 Cr..
- For Interest, as of Jun 2025, the value is 1.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.00 Cr. (Mar 2025) to 1.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 6.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 54.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 54.00 Cr..
- For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 23.00% (Mar 2025) to 26.00%, marking an increase of 3.00%.
- For Net Profit, as of Jun 2025, the value is 40.00 Cr.. The value appears to be declining and may need further review. It has decreased from 42.00 Cr. (Mar 2025) to 40.00 Cr., marking a decrease of 2.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 32.86. The value appears to be declining and may need further review. It has decreased from 34.60 (Mar 2025) to 32.86, marking a decrease of 1.74.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 5:01 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 178 | 219 | 314 | 427 | 602 | 702 | 742 | 627 | 1,048 | 1,404 | 1,488 | 1,745 | 1,838 |
| Expenses | 181 | 212 | 288 | 408 | 560 | 666 | 698 | 607 | 966 | 1,276 | 1,303 | 1,520 | 1,607 |
| Operating Profit | -3 | 6 | 27 | 19 | 41 | 35 | 43 | 20 | 82 | 128 | 185 | 225 | 230 |
| OPM % | -2% | 3% | 8% | 5% | 7% | 5% | 6% | 3% | 8% | 9% | 12% | 13% | 13% |
| Other Income | 0 | 0 | 1 | 4 | 6 | 4 | 3 | 6 | -22 | 2 | 3 | 9 | 13 |
| Interest | 7 | 8 | 7 | 2 | 2 | 2 | 4 | 3 | 5 | 7 | 6 | 7 | 6 |
| Depreciation | 3 | 3 | 3 | 3 | 6 | 8 | 9 | 11 | 13 | 14 | 18 | 22 | 25 |
| Profit before tax | -12 | -5 | 17 | 18 | 39 | 29 | 33 | 12 | 41 | 110 | 164 | 206 | 213 |
| Tax % | -31% | -35% | 38% | 30% | 36% | 35% | 26% | 55% | 26% | 26% | 25% | 26% | |
| Net Profit | -8 | -3 | 11 | 12 | 25 | 19 | 25 | 5 | 31 | 81 | 123 | 153 | 157 |
| EPS in Rs | -6.95 | -2.49 | 8.93 | 10.24 | 20.35 | 15.74 | 20.33 | 4.39 | 25.29 | 67.22 | 101.17 | 126.22 | 126.42 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 10% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 62.50% | 466.67% | 9.09% | 108.33% | -24.00% | 31.58% | -80.00% | 520.00% | 161.29% | 51.85% | 24.39% |
| Change in YoY Net Profit Growth (%) | 0.00% | 404.17% | -457.58% | 99.24% | -132.33% | 55.58% | -111.58% | 600.00% | -358.71% | -109.44% | -27.46% |
Kingfa Science & Technology (India) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 19% |
| 3 Years: | 19% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 48% |
| 5 Years: | 44% |
| 3 Years: | 48% |
| TTM: | 21% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 32% |
| 5 Years: | 56% |
| 3 Years: | 51% |
| 1 Year: | 29% |
| Return on Equity | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 18% |
| 3 Years: | 22% |
| Last Year: | 23% |
Last Updated: September 5, 2025, 9:05 am
Balance Sheet
Last Updated: June 16, 2025, 11:50 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 10 | 10 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 |
| Reserves | 5 | 2 | 109 | 234 | 293 | 312 | 336 | 342 | 372 | 454 | 576 | 716 |
| Borrowings | 62 | 75 | 16 | 42 | 21 | 17 | 46 | 71 | 46 | 42 | 33 | 43 |
| Other Liabilities | 31 | 41 | 95 | 119 | 159 | 210 | 202 | 246 | 449 | 502 | 373 | 384 |
| Total Liabilities | 105 | 125 | 230 | 405 | 485 | 551 | 596 | 671 | 880 | 1,010 | 994 | 1,156 |
| Fixed Assets | 24 | 25 | 29 | 76 | 88 | 85 | 107 | 129 | 126 | 123 | 252 | 244 |
| CWIP | 0 | 1 | 41 | 10 | 2 | 79 | 115 | 123 | 127 | 131 | 2 | 41 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 81 | 99 | 160 | 319 | 395 | 388 | 375 | 419 | 627 | 756 | 740 | 871 |
| Total Assets | 105 | 125 | 230 | 405 | 485 | 551 | 596 | 671 | 880 | 1,010 | 994 | 1,156 |
Below is a detailed analysis of the balance sheet data for Kingfa Science & Technology (India) Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 12.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 12.00 Cr..
- For Reserves, as of Mar 2025, the value is 716.00 Cr.. The value appears strong and on an upward trend. It has increased from 576.00 Cr. (Mar 2024) to 716.00 Cr., marking an increase of 140.00 Cr..
- For Borrowings, as of Mar 2025, the value is 43.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 33.00 Cr. (Mar 2024) to 43.00 Cr., marking an increase of 10.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 384.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 373.00 Cr. (Mar 2024) to 384.00 Cr., marking an increase of 11.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 1,156.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 994.00 Cr. (Mar 2024) to 1,156.00 Cr., marking an increase of 162.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 244.00 Cr.. The value appears to be declining and may need further review. It has decreased from 252.00 Cr. (Mar 2024) to 244.00 Cr., marking a decrease of 8.00 Cr..
- For CWIP, as of Mar 2025, the value is 41.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Mar 2024) to 41.00 Cr., marking an increase of 39.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 871.00 Cr.. The value appears strong and on an upward trend. It has increased from 740.00 Cr. (Mar 2024) to 871.00 Cr., marking an increase of 131.00 Cr..
- For Total Assets, as of Mar 2025, the value is 1,156.00 Cr.. The value appears strong and on an upward trend. It has increased from 994.00 Cr. (Mar 2024) to 1,156.00 Cr., marking an increase of 162.00 Cr..
Notably, the Reserves (716.00 Cr.) exceed the Borrowings (43.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -65.00 | -69.00 | 11.00 | -23.00 | 20.00 | 18.00 | -3.00 | -51.00 | 36.00 | 86.00 | 152.00 | 182.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 97 | 93 | 99 | 111 | 110 | 109 | 97 | 123 | 99 | 93 | 99 | 93 |
| Inventory Days | 54 | 64 | 85 | 69 | 85 | 63 | 67 | 100 | 110 | 94 | 76 | 82 |
| Days Payable | 66 | 72 | 127 | 108 | 108 | 119 | 115 | 152 | 181 | 155 | 110 | 94 |
| Cash Conversion Cycle | 85 | 85 | 57 | 72 | 86 | 53 | 49 | 71 | 28 | 32 | 66 | 80 |
| Working Capital Days | -7 | -14 | 66 | 59 | 96 | 59 | 55 | 57 | 39 | 45 | 78 | 85 |
| ROCE % | -9% | 4% | 22% | 9% | 13% | 9% | 10% | 4% | 16% | 25% | 30% | 31% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 126.22 | 101.17 | 67.22 | 25.29 | 4.39 |
| Diluted EPS (Rs.) | 126.22 | 101.17 | 67.22 | 25.29 | 4.39 |
| Cash EPS (Rs.) | 144.15 | 116.35 | 78.90 | 36.00 | 13.31 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 601.63 | 486.00 | 384.78 | 317.57 | 292.29 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 601.63 | 486.00 | 384.78 | 317.57 | 292.29 |
| Dividend / Share (Rs.) | 0.00 | 10.00 | 0.00 | 0.00 | 0.00 |
| Revenue From Operations / Share (Rs.) | 1440.64 | 1228.45 | 1159.08 | 865.13 | 517.93 |
| PBDIT / Share (Rs.) | 193.59 | 155.39 | 107.56 | 68.41 | 21.43 |
| PBIT / Share (Rs.) | 175.66 | 140.21 | 95.89 | 57.70 | 12.52 |
| PBT / Share (Rs.) | 170.16 | 135.58 | 90.49 | 34.14 | 9.79 |
| Net Profit / Share (Rs.) | 126.22 | 101.17 | 67.22 | 25.29 | 4.39 |
| PBDIT Margin (%) | 13.43 | 12.64 | 9.27 | 7.90 | 4.13 |
| PBIT Margin (%) | 12.19 | 11.41 | 8.27 | 6.66 | 2.41 |
| PBT Margin (%) | 11.81 | 11.03 | 7.80 | 3.94 | 1.88 |
| Net Profit Margin (%) | 8.76 | 8.23 | 5.79 | 2.92 | 0.84 |
| Return on Networth / Equity (%) | 20.97 | 20.81 | 17.47 | 7.96 | 1.50 |
| Return on Capital Employeed (%) | 29.00 | 28.66 | 24.65 | 17.08 | 3.92 |
| Return On Assets (%) | 13.22 | 12.32 | 8.05 | 3.49 | 0.79 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.04 | 0.06 |
| Total Debt / Equity (X) | 0.05 | 0.05 | 0.08 | 0.10 | 0.11 |
| Asset Turnover Ratio (%) | 1.62 | 1.48 | 1.49 | 1.35 | 0.98 |
| Current Ratio (X) | 2.02 | 1.80 | 1.37 | 1.30 | 1.45 |
| Quick Ratio (X) | 1.31 | 1.20 | 0.83 | 0.74 | 0.94 |
| Inventory Turnover Ratio (X) | 4.58 | 4.11 | 3.84 | 4.47 | 4.03 |
| Interest Coverage Ratio (X) | 35.23 | 33.55 | 19.95 | 15.67 | 7.84 |
| Interest Coverage Ratio (Post Tax) (X) | 23.97 | 22.84 | 13.47 | 11.19 | 2.61 |
| Enterprise Value (Cr.) | 3600.92 | 2398.91 | 1621.01 | 1546.18 | 724.65 |
| EV / Net Operating Revenue (X) | 2.06 | 1.61 | 1.15 | 1.48 | 1.16 |
| EV / EBITDA (X) | 15.36 | 12.75 | 12.44 | 18.66 | 27.92 |
| MarketCap / Net Operating Revenue (X) | 2.06 | 1.60 | 1.14 | 1.46 | 1.13 |
| Price / BV (X) | 4.92 | 4.03 | 3.45 | 3.99 | 2.00 |
| Price / Net Operating Revenue (X) | 2.06 | 1.60 | 1.14 | 1.46 | 1.13 |
| EarningsYield | 0.04 | 0.05 | 0.05 | 0.01 | 0.01 |
After reviewing the key financial ratios for Kingfa Science & Technology (India) Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 126.22. This value is within the healthy range. It has increased from 101.17 (Mar 24) to 126.22, marking an increase of 25.05.
- For Diluted EPS (Rs.), as of Mar 25, the value is 126.22. This value is within the healthy range. It has increased from 101.17 (Mar 24) to 126.22, marking an increase of 25.05.
- For Cash EPS (Rs.), as of Mar 25, the value is 144.15. This value is within the healthy range. It has increased from 116.35 (Mar 24) to 144.15, marking an increase of 27.80.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 601.63. It has increased from 486.00 (Mar 24) to 601.63, marking an increase of 115.63.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 601.63. It has increased from 486.00 (Mar 24) to 601.63, marking an increase of 115.63.
- For Dividend / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. It has decreased from 10.00 (Mar 24) to 0.00, marking a decrease of 10.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,440.64. It has increased from 1,228.45 (Mar 24) to 1,440.64, marking an increase of 212.19.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 193.59. This value is within the healthy range. It has increased from 155.39 (Mar 24) to 193.59, marking an increase of 38.20.
- For PBIT / Share (Rs.), as of Mar 25, the value is 175.66. This value is within the healthy range. It has increased from 140.21 (Mar 24) to 175.66, marking an increase of 35.45.
- For PBT / Share (Rs.), as of Mar 25, the value is 170.16. This value is within the healthy range. It has increased from 135.58 (Mar 24) to 170.16, marking an increase of 34.58.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 126.22. This value is within the healthy range. It has increased from 101.17 (Mar 24) to 126.22, marking an increase of 25.05.
- For PBDIT Margin (%), as of Mar 25, the value is 13.43. This value is within the healthy range. It has increased from 12.64 (Mar 24) to 13.43, marking an increase of 0.79.
- For PBIT Margin (%), as of Mar 25, the value is 12.19. This value is within the healthy range. It has increased from 11.41 (Mar 24) to 12.19, marking an increase of 0.78.
- For PBT Margin (%), as of Mar 25, the value is 11.81. This value is within the healthy range. It has increased from 11.03 (Mar 24) to 11.81, marking an increase of 0.78.
- For Net Profit Margin (%), as of Mar 25, the value is 8.76. This value is within the healthy range. It has increased from 8.23 (Mar 24) to 8.76, marking an increase of 0.53.
- For Return on Networth / Equity (%), as of Mar 25, the value is 20.97. This value is within the healthy range. It has increased from 20.81 (Mar 24) to 20.97, marking an increase of 0.16.
- For Return on Capital Employeed (%), as of Mar 25, the value is 29.00. This value is within the healthy range. It has increased from 28.66 (Mar 24) to 29.00, marking an increase of 0.34.
- For Return On Assets (%), as of Mar 25, the value is 13.22. This value is within the healthy range. It has increased from 12.32 (Mar 24) to 13.22, marking an increase of 0.90.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.05. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.05.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.62. It has increased from 1.48 (Mar 24) to 1.62, marking an increase of 0.14.
- For Current Ratio (X), as of Mar 25, the value is 2.02. This value is within the healthy range. It has increased from 1.80 (Mar 24) to 2.02, marking an increase of 0.22.
- For Quick Ratio (X), as of Mar 25, the value is 1.31. This value is within the healthy range. It has increased from 1.20 (Mar 24) to 1.31, marking an increase of 0.11.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.58. This value is within the healthy range. It has increased from 4.11 (Mar 24) to 4.58, marking an increase of 0.47.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 35.23. This value is within the healthy range. It has increased from 33.55 (Mar 24) to 35.23, marking an increase of 1.68.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 23.97. This value is within the healthy range. It has increased from 22.84 (Mar 24) to 23.97, marking an increase of 1.13.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,600.92. It has increased from 2,398.91 (Mar 24) to 3,600.92, marking an increase of 1,202.01.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.06. This value is within the healthy range. It has increased from 1.61 (Mar 24) to 2.06, marking an increase of 0.45.
- For EV / EBITDA (X), as of Mar 25, the value is 15.36. This value exceeds the healthy maximum of 15. It has increased from 12.75 (Mar 24) to 15.36, marking an increase of 2.61.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.06. This value is within the healthy range. It has increased from 1.60 (Mar 24) to 2.06, marking an increase of 0.46.
- For Price / BV (X), as of Mar 25, the value is 4.92. This value exceeds the healthy maximum of 3. It has increased from 4.03 (Mar 24) to 4.92, marking an increase of 0.89.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.06. This value is within the healthy range. It has increased from 1.60 (Mar 24) to 2.06, marking an increase of 0.46.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 0.05 (Mar 24) to 0.04, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Kingfa Science & Technology (India) Ltd:
- Net Profit Margin: 8.76%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 29% (Industry Average ROCE: 16.69%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 20.97% (Industry Average ROE: 12.44%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 23.97
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.31
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 35.1 (Industry average Stock P/E: 36.45)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.05
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 8.76%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Plastics - Plastic & Plastic Products | Dhun Building, 3rd Floor, Chennai (Madras) Tamil Nadu 600002 | cs@kingfaindia.com http://www.kingfaindia.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Bo Jingen | Managing Director |
| Mr. Doraiswami Balaji | Executive Director |
| Mr. Sun Yajie | Executive Director |
| Ms. Nilima Ramrao Shinde | Ind. Non-Executive Director |
| Mr. S K Subramanyan | Ind. Non-Executive Director |
| Mr. Ramachandran Sudhinder | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Kingfa Science & Technology (India) Ltd?
Kingfa Science & Technology (India) Ltd's intrinsic value (as of 25 November 2025) is 6345.83 which is 57.94% higher the current market price of 4,018.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 5,522 Cr. market cap, FY2025-2026 high/low of 4,987/2,451, reserves of ₹716 Cr, and liabilities of 1,156 Cr.
What is the Market Cap of Kingfa Science & Technology (India) Ltd?
The Market Cap of Kingfa Science & Technology (India) Ltd is 5,522 Cr..
What is the current Stock Price of Kingfa Science & Technology (India) Ltd as on 25 November 2025?
The current stock price of Kingfa Science & Technology (India) Ltd as on 25 November 2025 is 4,018.
What is the High / Low of Kingfa Science & Technology (India) Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Kingfa Science & Technology (India) Ltd stocks is 4,987/2,451.
What is the Stock P/E of Kingfa Science & Technology (India) Ltd?
The Stock P/E of Kingfa Science & Technology (India) Ltd is 35.1.
What is the Book Value of Kingfa Science & Technology (India) Ltd?
The Book Value of Kingfa Science & Technology (India) Ltd is 955.
What is the Dividend Yield of Kingfa Science & Technology (India) Ltd?
The Dividend Yield of Kingfa Science & Technology (India) Ltd is 0.00 %.
What is the ROCE of Kingfa Science & Technology (India) Ltd?
The ROCE of Kingfa Science & Technology (India) Ltd is 30.6 %.
What is the ROE of Kingfa Science & Technology (India) Ltd?
The ROE of Kingfa Science & Technology (India) Ltd is 23.2 %.
What is the Face Value of Kingfa Science & Technology (India) Ltd?
The Face Value of Kingfa Science & Technology (India) Ltd is 10.0.